Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Cannabis Science Provides Product Line Guidance With Summary of Products In Development And Available On The Market Today

Cannabis Science Inc.
Posted on: 25 Apr 12

Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is providing an update and summary of our goals and product line advancements. Some products are currently available to patients with legal state medical marijuana access, and others are up and coming over-the-counter products that will be available to the public nationally and internationally.

Cannabis Science is currently working towards making critical cannabis-based medications more widely available. To this aim, we have initiated, with our FDA advisory group, the pre-IND process. Unlike most conventional treatments, cannabis medicines and formulations have an outstanding safety profile, going back thousands of years. They allow patients in states with medical cannabis laws to safely make informed decisions to legally self-administer various cannabis-based preparations.

The medication will specifically target skin cancers including basal and squamous cell carcinomas. Judging by the results of the squamous cell carcinoma treatment studies Cannabis Science has already undertaken (see cannabisscience.com), we believe we have a breakthrough treatment for squamous cell carcinomas that are resistant to convention chemo- and radiation therapies.

Currently, Cannabis Science has cannabis-based, high quality oil available in Pueblo and Denver Colorado through licensing agreements. The oil, is packaged in oral dispensing syringes for patient self-administration. We have received excellent feedback regarding these products, specifically from patients suffering cancer and chronic pain.

In addition to the license agreements with dispensary and FDA products, Cannabis Science is very excited about the over the counter skin and nutraceutical product lines that are currently in development. Sunscreen, skin and face moisturizer, lip balm, and anti-aging serum will be available over the counter in drugstores and other retail outlets. Dr. Moe Afaneh, Cannabis Science’s Chief Operations Officer, is heading the development of this product line, and with his decade of successful experience in pharmaceutical product marketing, branding, and compounding prescriptions, he is aiding Cannabis Science tremendously in moving these projects forward. Cannabis Science is also in final discussions to finalize the brand name for the initial product line.

The Company's intent is to work with specially appointed legal providers and laboratories to expand the availability of its formulations across the United States and the world where legally available.

Dr. Bob Melamede stated “Cannabis Science is excited that we are developing profit centers that will come online and create revenue in 2012. In addition to the revenues that we believe will be created with the Cannabis Extract Based prescription medicines and over-the-counter formulations, Cannabis Science has the ability to generate revenues now through the partnership with Vincent Mehdizadeh of Medical Dispensing Solutions, and consulting revenues Kaneabis acquisition. It is our goal to self- fund the FDA IND application and approval process as much as possible, that funding is generated from these additional profit centers.”

About Cannabis Science, Inc.Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

www.cannabisscience.com

Forward Looking StatementsThis Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Business Wire
http://www.businesswire.com/

Last updated on: 25/04/2012

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.